Biosign Investor Update

Biosign to begin Retail Sales of Pulsewave™

TORONTO, June 11, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") made the following statement:

Biosign is pleased to announce the launch of a new e-commerce initiative. For the first time, the general public may now purchase the Health Canada approved Pulsewave™ Monitor system directly from Biosign at www.store.biosign.com.

Initially two packages will be available: Pulsewave™ Personal ($199.00 + tax & shipping) is designed for one individual user, while Pulsewave™ Family ($229.00 + tax & shipping) is set up in such a way that up to five family members can share the use of one Pulsewave™ Pulse Acquisition Device (PAD). Each Pulsewave™ package includes the innovative Pulsewave™ device and one year of free access to a secure, encrypted online account where the each user's readings, charts & reports are accessible from any web browser.  After the initial free year, a renewal fee of $23.99/year (Personal) or $35.99/year (Family) will be automatically billed to the user for continued access to readings & historical data. Simultaneously, Biosign will also make these Pulsewave™ Personal & Pulsewave™ Family packages available at www.amazon.ca.

Biosign further announces a new retail promotion in conjunction with our popular Heart Friendly™ heart-health screening program. Starting immediately, customers who are screened at any Heart Friendly™ Practice in Canada will receive a coupon entitling them to a substantial discount on either Pulsewave™ package at www.store.biosign.com.

With the recently announced reseller relationship between Biosign and ClinicServer, the Company intends to expand the Heart Friendly™ Program beyond dentists and into allied health clinics across Canada and the United States. Since the launch of Heart Friendly™ Dentist, over 40,000 Canadians have received a Heart Friendly™ reading & report. By promoting the sale of Pulsewave™ units for use at home in partnership with our Heart Friendly™ practitioners, Biosign believes that overall health outcomes for users will be enhanced, and we will also give our clinician partners an important new way to benefit from the Heart Friendly™ program.

Biosign CEO Robert Kaul commented, "We have received excellent feedback from Pulsewave™ users. In one recent survey, conducted by the Dental Health Group in Burlington ON, 80% of patients surveyed found it beneficial or important to have a Pulsewave™ reading taken at their dental appointment, while 86% felt that the information provided about their heart-health was useful to them. This level of support gives us confidence that our consumer promotion will be successful, and that health-conscious customers will choose to continue monitoring their hearts using Pulsewave™ at home."

The Biosign Pulsewave™ Monitor is an end-to-end solution for non-invasive monitoring, analysis and reporting of health data. The Pulsewave™ cuff painlessly captures the pulse waveform from a person's radial artery and transmits it to the secure servers in the cloud. Biosign algorithms are employed to analyze the data in seconds in order to generate reports that include blood pressure, heart beat anomalies and other vital sign measurements. Pulsewave™ is the only OTC health monitor that shows the actual heart beating - live, in real-time. In addition, online Pulsewave™ analysis and reporting tools give patients and healthcare providers secure access to current and historical health information.

Completion of shares for debt transaction

The Company agreed to convert $221,493.73 owing to approximately 12 parties, two of whom are related parties as they are an officer and/or director of the Company (the "Indebtedness"), into common shares at a price of $0.05 per share. Subject to all applicable regulations, 4,429,874 common shares shall be issued in full satisfaction of the Indebtedness.

Biosign CEO Robert Kaul stated: "This conversion of debt to equity allows us to preserve cash during a difficult economic climate, and thereby maximize funds to pursue our sales objectives".

About Biosign Technologies Inc:

Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled health information products. Key applications include the noninvasive monitoring of vital signs including blood pressure, pulse rate and breathing rate, enhanced with web services. The Company's Pulsewave™ medical device technology powers data collection for clinical decision support, self-care, wellness and disease management, while its Healthanywhere™ software suite offers industry-leading remote patient monitoring solutions. The Company offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Dentist. For more information on Biosign, please visit www.biosign.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


SOURCE: Biosign Technologies Inc.

For further information:

Contact Information for Biosign:

Robert Kaul
Chief Executive Officer
Biosign Technologies
Phone: (416) 218-9800 ext. 201
Email: ceo@biosign.com

Organization Profile

Biosign Technologies Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890